Oppenheimer Asset Management Inc. cut its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 232,409 shares of the company's stock after selling 6,723 shares during the quarter. Oppenheimer Asset Management Inc. owned approximately 0.05% of Zoetis worth $37,866,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in Zoetis during the 3rd quarter valued at about $31,000. First Personal Financial Services purchased a new stake in Zoetis during the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP purchased a new stake in Zoetis during the 3rd quarter valued at about $33,000. Finally, Dunhill Financial LLC boosted its holdings in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after acquiring an additional 75 shares during the period. 92.80% of the stock is currently owned by institutional investors.
Insider Activity at Zoetis
In related news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company's stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.
Zoetis Stock Up 1.6 %
Shares of ZTS traded up $2.60 on Friday, reaching $167.58. The stock had a trading volume of 3,333,297 shares, compared to its average volume of 3,283,954. The firm has a market capitalization of $75.04 billion, a price-to-earnings ratio of 30.64, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a 50-day simple moving average of $166.30 and a 200-day simple moving average of $177.30. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53.
Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.
Zoetis Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is presently 36.56%.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on ZTS. Leerink Partnrs upgraded Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. Piper Sandler increased their target price on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. StockNews.com cut Zoetis from a "buy" rating to a "hold" rating in a report on Tuesday, February 25th. Finally, Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $215.90.
Get Our Latest Report on ZTS
About Zoetis
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
